Tarsus Pharmaceuticals, Inc. ·
TARS 8-K 2026-09-10
Tarsus Pharmaceuticals, Inc. (TARS) 8-K dated 2026-09-10 — accession 0001819790-26-000066.
Tarsus Pharmaceuticals, Inc. (TARS) is a biotechnology company listed on NASDAQ.
Tarsus Pharmaceuticals, Inc. filed a 8-K on 2026-09-10. Accession 0001819790-26-000066.
This 8-K covers: Acquisition or disposition (Item 2.01), Other events (Item 8.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported TARS revenue for 2025-12-31 was $451.4M. Net income was -$66.4M. Revenue was up 146.7% from 2024-12-31 to 2025-12-31. TARS currently screens at market cap $2.66B.
Not investment advice. The TARS SEC hub lists recent forms. The stock page is the research view.